GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Pre-Tax Income

CG Oncology (CG Oncology) Pre-Tax Income : $-33.05 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. CG Oncology's pretax income for the three months ended in Mar. 2024 was $-16.93 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.05 Mil. CG Oncology's pretax margin was -3,200.76%.

During the past 3 years, CG Oncology's highest Pretax Margin was -123.95%. The lowest was -23826.96%. And the median was -18556.54%.

CG Oncology Pre-Tax Income Historical Data

The historical data trend for CG Oncology's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Pre-Tax Income Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Pre-Tax Income
-12.84 -35.44 -48.61

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial -8.39 -8.67 - -16.12 -16.93

Competitive Comparison of CG Oncology's Pre-Tax Income

For the Biotechnology subindustry, CG Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where CG Oncology's Pre-Tax Income falls into.


CG Oncology Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

CG Oncology's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-55.449+-0.062+0+0+6.904
=-48.61

CG Oncology's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-22.469+-0.009+0+5.546+3.5527136788005E-15
=-16.93

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology  (NAS:CGON) Pre-Tax Income Explanation

CG Oncology's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-16.932/0.529
=-3,200.76%

During the past 3 years, CG Oncology's highest Pretax Margin was -123.95%. The lowest was -23826.96%. And the median was -18556.54%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of CG Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Pre-Tax Income
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024